SAB Biotherapeutics, Inc. financial data

Symbol
SABS, SABSW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
777 W 41 St St, Suite 401, Miami Beach, Florida
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Big Cypress Acquisition Corp. (to 10/22/2021)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 414 % +244%
Debt-to-equity 43.2 % -39.7%
Return On Equity -94 % +14.8%
Return On Assets -65.7 % -2.13%
Operating Margin -1.65K % -258%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9.23M shares -82.4%
Common Stock, Shares, Outstanding 9.23M shares -82.4%
Entity Public Float 30.7M USD -6.22%
Common Stock, Value, Issued 929 USD -82.4%
Weighted Average Number of Shares Outstanding, Basic 9.26M shares +83.6%
Weighted Average Number of Shares Outstanding, Diluted 9.26M shares +83.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 85.5K USD -98.7%
Revenue from Contract with Customer, Excluding Assessed Tax 2.78M USD -56.7%
Research and Development Expense 23.3M USD +2.45%
General and Administrative Expense 25.3M USD +91%
Operating Income (Loss) -45.8M USD -55%
Nonoperating Income (Expense) 5.47M USD +1316%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -40.3M USD -38.3%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -40.3M USD -38.2%
Earnings Per Share, Basic -6.15 USD/shares +12.6%
Earnings Per Share, Diluted -6.15 USD/shares +12.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.2M USD +122%
Cash, Cash Equivalents, and Short-term Investments 15M USD -62%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 39.6M USD +339%
Property, Plant and Equipment, Net 16.9M USD -21.4%
Operating Lease, Right-of-Use Asset 1.24M USD +70%
Assets 61.9M USD +74.6%
Accounts Payable, Current 1.17M USD -16.6%
Employee-related Liabilities, Current 2.84M USD
Liabilities, Current 7.55M USD -31.4%
Operating Lease, Liability, Noncurrent 782K USD +752%
Liabilities 15.8M USD +0.29%
Accumulated Other Comprehensive Income (Loss), Net of Tax -31.4K USD
Retained Earnings (Accumulated Deficit) -102M USD -64.9%
Stockholders' Equity Attributable to Parent 46.1M USD +134%
Liabilities and Equity 61.9M USD +74.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.8M USD -569%
Net Cash Provided by (Used in) Financing Activities -394K USD -9.63%
Net Cash Provided by (Used in) Investing Activities -31.4M USD -147126%
Common Stock, Shares Authorized 800M shares +63.3%
Common Stock, Shares, Issued 9.28M shares -82.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -42.5M USD -2041%
Interest Paid, Excluding Capitalized Interest, Operating Activities 66.2K USD -15.5%
Deferred Tax Assets, Valuation Allowance 19.2M USD +55.9%
Deferred Tax Assets, Gross 22.1M USD +39.5%
Operating Lease, Liability 1.24M USD +94.6%
Payments to Acquire Property, Plant, and Equipment 129K USD +506%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -7.3M USD -6.14%
Lessee, Operating Lease, Liability, to be Paid 1.39M USD +110%
Property, Plant and Equipment, Gross 29.8M USD +0.73%
Operating Lease, Liability, Current 459K USD -16%
Lessee, Operating Lease, Liability, to be Paid, Year Two 393K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 452K USD +22.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +15.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 147K USD +532%
Lessee, Operating Lease, Liability, to be Paid, Year Three 86.7K USD
Deferred Tax Assets, Operating Loss Carryforwards 10.3M USD +84.2%
Preferred Stock, Shares Issued 42.2K shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 90.2K USD
Operating Lease, Payments 841K USD +3.06%
Additional Paid in Capital 154M USD +76.4%
Preferred Stock, Shares Outstanding 42.2K shares
Depreciation, Depletion and Amortization 4.82M USD +34.5%
Deferred Tax Assets, Net of Valuation Allowance 2.86M USD -18.2%
Share-based Payment Arrangement, Expense 2.4M USD -2.42%
Interest Expense 317K USD -2.75%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%